Alan M Walfield

Title: Innovations by Alan M. Walfield in Allergy Treatment

Introduction

Alan M. Walfield is an accomplished inventor based in Huntington Station, NY, holding a notable portfolio of two patents. His innovative work primarily addresses the challenges associated with allergy treatment through the development of novel peptide compositions.

Latest Patents

One of Alan's latest patents, titled "Peptide Composition as Immunogen for the Treatment of Allergy," focuses on peptides that contain sequences homologous to a portion of the third constant domain of the epsilon heavy chain of IgE. These peptides are covalently linked to either a carrier protein or a helper T cell epitope, and may also include additional immunostimulatory sequences. The invention aims to elicit the production of high titer polyclonal antibodies in mammals that specifically target a crucial effector site on the epsilon heavy chain of IgE. This invention holds potential for pharmaceutical compositions, providing a novel immunotherapy approach for IgE-mediated allergic diseases.

The patent reinforces the potential utility of these peptides within the biomedical field, particularly in developing targeted treatments for those suffering from allergies.

Career Highlights

Alan currently contributes his expertise at United Biomedical, Inc., where he focuses on advancing biotechnological innovations aimed at improving health outcomes. His solid background and dedicated research allow him to make significant strides in the field of immunotherapy.

Collaborations

Working alongside his coworker Chang Yi Wang, Alan continues to explore and develop innovative solutions in allergy treatment. Their collaboration enhances the scope and impact of their research, combining their skills to push the boundaries of current medical practices.

Conclusion

In summary, Alan M. Walfield's contributions through his patents showcase his commitment to advancing allergy treatment methodologies. His innovative peptide compositions offer promising avenues for immunotherapy, which may greatly benefit individuals affected by IgE-mediated allergic diseases. As he continues his work at United Biomedical, Inc., the impact of his innovations is expected to grow, highlighting the importance of research in combating health challenges.